Eleven-year experience with composite graft replacement of the ascending aorta and aortic valve.
Journal of Thoracic and Cardiovascular Surgery 1986 October
Between September, 1974, and December, 1985, 127 patients had replacement of the ascending aorta and aortic valve with a composite graft. Annuloaortic ectasia was the most common indication for operation (69 patients), followed by aortic dissection (51 patients). Twenty-four patients (19%) had the Marfan syndrome. Hospital mortality was 4.7%. Emergent operation for acute dissection was the only independent predictor of hospital death (p = 0.03). Reoperation for postoperative hemorrhage was required in 15 patients (11.8%) and for prosthesis-related complications (pseudoaneurysm, prosthetic endocarditis, technical problems, and valve thrombosis) in 16 patients (12.6%). Since we adopted a technique of preclotting the prosthesis with whole blood or albumin plus autoclaving and abandoned the inclusion technique, the reoperation rate has declined substantially. At 5 years, the actuarial freedom from reoperation for any reason on the ascending aorta or aortic valve for the 24 patients in whom this modification was used was 90% and for the remaining 103 patients, 73% (p = 0.17). No reoperations for pseudoaneurysms or technical problems were required in these 24 patients, whereas 10 reoperations for these complications were necessary in the other patients. The mean duration of follow-up was 54 months. The actuarial survival rate at 7 years for the entire group was 65%; for the patients with annuloaortic ectasia, 70%; for those with aortic dissection, 61%; for the patients with the Marfan syndrome, 57%. Actuarial freedom from operation on the remainder of the aorta at 7 years was 89%, but it was 78% for the subgroup with the Marfan syndrome. The satisfactory results with extended follow-up support the continued use of the composite graft technique as the preferred method of treatment for patients with annuloaortic ectasia or recurrent aneurysms of the sinuses of Valsalva and for patients with aortic dissection who require aortic valve replacement.
Full text links
Trending Papers
Carvedilol, probably the β-blocker of choice for everyone with cirrhosis and portal hypertension: But not so fast!Liver International : Official Journal of the International Association for the Study of the Liver 2023 June
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis.Nature Reviews. Rheumatology 2023 May 10
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app